ES2673899T3 - Receptores de tipo toll y oligonucleótidos inmunoestimuladores - Google Patents

Receptores de tipo toll y oligonucleótidos inmunoestimuladores Download PDF

Info

Publication number
ES2673899T3
ES2673899T3 ES13731800.2T ES13731800T ES2673899T3 ES 2673899 T3 ES2673899 T3 ES 2673899T3 ES 13731800 T ES13731800 T ES 13731800T ES 2673899 T3 ES2673899 T3 ES 2673899T3
Authority
ES
Spain
Prior art keywords
oligodeoxynucleotide
vaccine
toll
receptors
immunostimulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13731800.2T
Other languages
English (en)
Inventor
Thomas Simon Ilg
Jaap KOOL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Application granted granted Critical
Publication of ES2673899T3 publication Critical patent/ES2673899T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)

Abstract

Vacuna para su uso en la prevencion o la lucha contra una enfermedad infecciosa, caracterizada por que dicha vacuna comprende una cantidad inmunoestimuladora de un oligodesoxinucleotido PTO inmunoestimulador no metilado que tiene la formula general [tcg]n en la que n>=6, o dicho oligodesoxinucleotido acoplado a un vehiculo o a un hapteno, y/o un vector que comprende el oligodesoxinucleotido, en donde la vacuna comprende ademas una cantidad inmunologica de un componente antigenico, o la informacion genetica que codifica un componente antigenico, y un vehiculo farmaceuticamente aceptable.
ES13731800.2T 2012-06-28 2013-06-27 Receptores de tipo toll y oligonucleótidos inmunoestimuladores Active ES2673899T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12174199 2012-06-28
EP12174199 2012-06-28
PCT/EP2013/063452 WO2014001422A2 (en) 2012-06-28 2013-06-27 Toll-like receptors

Publications (1)

Publication Number Publication Date
ES2673899T3 true ES2673899T3 (es) 2018-06-26

Family

ID=48699818

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13731800.2T Active ES2673899T3 (es) 2012-06-28 2013-06-27 Receptores de tipo toll y oligonucleótidos inmunoestimuladores

Country Status (14)

Country Link
US (1) US10112985B2 (es)
EP (1) EP2867249B1 (es)
JP (1) JP6427487B2 (es)
KR (1) KR20150023465A (es)
CN (1) CN104718221B (es)
AR (1) AR091569A1 (es)
AU (1) AU2013283359A1 (es)
CA (1) CA2873288A1 (es)
ES (1) ES2673899T3 (es)
MX (1) MX2014015766A (es)
NZ (1) NZ701803A (es)
RU (1) RU2015102611A (es)
WO (1) WO2014001422A2 (es)
ZA (1) ZA201408773B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180003A (es) * 2015-06-26 2018-03-20 Bayer Animal Health Gmbh Métodos de modulación de moléculas de vigilancia de adn citosólicas
CN114807152A (zh) 2016-06-08 2022-07-29 哈佛学院院长及董事 工程化病毒载体减少了炎症和免疫反应的诱导
BR112020011815A2 (pt) 2017-12-15 2020-11-17 Bayer Animal Health Gmbh oligonucleotídeos imunoestimulatórios
US20210364497A1 (en) * 2018-04-02 2021-11-25 University Of Miami IFN-beta Reporter System for Primary Cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696338B2 (en) * 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US5948677A (en) 1996-12-09 1999-09-07 Jarvik; Jonathan W. Reading frame independent epitope tagging
CA2399550A1 (en) * 2000-02-23 2001-08-30 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
CN1271733A (zh) 2000-04-04 2000-11-01 中国预防医学科学院病毒学研究所 对人免疫细胞有特异免疫刺激活性的CpG寡核酸
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
WO2004026888A2 (en) * 2002-09-19 2004-04-01 Coley Pharmaceutical Gmbh Toll-like receptor 9 (tlr9) from various mammalian species
US8163506B2 (en) 2003-06-17 2012-04-24 Meiji Co., Ltd. Use of toll-like receptor-expressing cells
JP3976742B2 (ja) 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
US7647679B2 (en) 2007-07-03 2010-01-19 Hardinge, Inc. Belt-driven indexing tool turret assembly
FR2954703B1 (fr) 2009-12-28 2013-12-13 Chu Nantes Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
PL2714908T3 (pl) 2011-05-26 2018-07-31 Intervet International B.V. Oligodeoksynukleotydy immunostymulacyjne
US9359602B2 (en) 2011-05-26 2016-06-07 Intervet Inc. Immunostimulatory oligodeoxynucleotides

Also Published As

Publication number Publication date
CN104718221B (zh) 2018-06-26
EP2867249A2 (en) 2015-05-06
AR091569A1 (es) 2015-02-11
CA2873288A1 (en) 2014-01-03
EP2867249B1 (en) 2018-04-18
US20150191523A1 (en) 2015-07-09
WO2014001422A3 (en) 2014-02-27
ZA201408773B (en) 2015-12-23
KR20150023465A (ko) 2015-03-05
RU2015102611A (ru) 2016-08-20
MX2014015766A (es) 2015-04-10
CN104718221A (zh) 2015-06-17
AU2013283359A1 (en) 2014-11-27
WO2014001422A2 (en) 2014-01-03
JP6427487B2 (ja) 2018-11-21
US10112985B2 (en) 2018-10-30
JP2015522266A (ja) 2015-08-06
NZ701803A (en) 2017-06-30

Similar Documents

Publication Publication Date Title
CL2016000650A1 (es) Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
CO6382137A2 (es) Oligonucleótidos inmunoestimuladores
EA201291157A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
WO2011027222A3 (en) Immunogenic compositions including tlr activity modulators
MX360448B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
MX2012002654A (es) Compuestos y composiciones como moduladores de la actividad de tlr.
PT2121011E (pt) Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
ZA200906753B (en) Oil-in-water emulsion influenza vaccine
BR112013016683A2 (pt) oligodesoxinucleotídeo não metilado imunoestimulatório, vetor, vacina para prevenir ou combater uma doença infecciosa, célula, e, método para a detecção de oligodesoxinucleotídeos imunoestimulatórios.
BR112013025045A2 (pt) anticorpos direcionados contra icos e usos dos mesmos
IN2015DN00694A (es)
BR112013029966A2 (pt) oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, e, vacina para prevenir ou combater uma doença infecciosa
BR112013029968A2 (pt) oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, vacina para prevenir ou combater uma doença infecciosa, e, método para a detecção de oligodesoxinucleotídeos imunoestimulatórios
CR20150170A (es) Vacunas de inmersión subunidad para peces
EA201001045A1 (ru) Модифицированный вирус гриппа
WO2012067866A3 (en) Multivalent vaccine for filariasis
BRPI0810865A2 (pt) antígenos de tripanossoma, composições vacinais, e métodos relacionados
ES2673899T3 (es) Receptores de tipo toll y oligonucleótidos inmunoestimuladores
BR112017015288A2 (pt) vacina contra febre aftosa
EP2762153A3 (en) Vaccine composition for mucosal administration
HK1219052A1 (zh) 針對典型性豬瘟病毒的嵌合疫苗抗原
AR097029A1 (es) Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
BRPI0917447A2 (pt) vacinas para bronquite infecciosa derivada de cepas similres a ib-qx
WO2011100408A3 (en) Serologic correlates of protection against bacillis anthracis infection
CR11755A (es) Dronedarona para la prevencion de la cardioversion